Bruce A. Feinberg, DO

Research Reports

Community Oncologists‚ Perception and Adaptability to Emerging Chimeric Antigen T-Cell Therapy

10/16/2017

Abstract: The Oncologic Drugs Advisory Committee recently voted 10-0 recommending to the Food and Drug Administration (FDA) the approval of the first chimeric antigen receptor T (CAR-T) therapy. We sought to better...

...

10/16/2017

Journal of Clinical Pathways

Research Reports

The Role and Scope of Practice of Advanced Practice Providers in United States Community Oncology

04/21/2020

Ajeet Gajra , MD, FACP;

Ting-Chun Yeh , PhD;

Chadi Nabhan , MD, MBA, FACP;

Yolaine J. Jeune-Smith , PhD;

Bruce A. Feinberg , DO;

Andrew J. Klink , PhD, MPH;

Bela Bapat , MS;

Abstract: In the era of value-based care and constrained resources, oncology practices are increasingly employing advanced practice providers (APPs) to improve practice workflow, increase efficiency, and enable...

...

04/21/2020

Journal of Clinical Pathways

$Real-World Management and Outcomes of Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated in the United States$

Research Reports

Real-World Management and Outcomes of Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated in the United States

02/18/2020

Andrew J. Klink , PhD, MPH;

Anna G. Purdum , PharmD, MS;

Chadi Nabhan , MD, MBA, FACP;

Bruce A. Feinberg , DO;

Choo Hyung Lee , MS;

Yin Yang , MS;

JaLyna Laney , RN, OCN;

Abstract: Given new therapeutic advances that are potentially curative in diffuse large B-cell lymphoma (DLBCL), it is important to understand what has been observed to date in this population to assess improvement...

...

02/18/2020

Journal of Clinical Pathways

Counterpoint

CAR-T Therapies: Placing Patient Safety First

08/22/2018

Chadi Nabhan , MD, MBA, FACP;

Bruce A. Feinberg , DO;

The commercial success and ability of eligible patients to receive chimeric antigen receptor T-cell (CAR-T) therapies depend on optimizing the logistics of delivering this transformational treatment platform. One...

The...

08/22/2018

Journal of Clinical Pathways

Counterpoint

Understanding Provider Perceptions Is Key to Utilization and Uptake of CAR-T Therapy

04/17/2018

Bruce A. Feinberg , DO;

Chadi Nabhan , MD, MBA, FACP;

The potential impact of chimeric antigen receptor T-cell (CAR-T) therapies should not be underestimated, nor should their complexity. There is much to consider when reprogramming patients’ own immune cells. As most...

The...

04/17/2018

Journal of Clinical Pathways

Counterpoint

The Pivot Toward Patient-Centeredness in Medicine and Oncology

09/06/2016

Jennifer Fillman , MBA;

Julia Braverman , PhD;

Bruce A. Feinberg , DO;

Patient-reported outcome (PRO) research has shown that PROs must play a role in the future of health care delivery as the system transitions from volume-based care to value-based care. Building trust among...

...

09/06/2016

Journal of Clinical Pathways

Guest Blog

Why Payers, Other Stakeholders Should Remain Optimistic About CAR-T Therapies

03/15/2018

Bruce A. Feinberg , DO;

Chadi Nabhan , MD, MBA, FACP;

Bruce A Feinberg, DO, and Chadi Nabhan, MD, MBA, FACP, contend that collaboration between payers and other stakeholders will help amend the concerns regarding newly approved CAR-T therapies.

Bruce A Feinberg, DO, and Chadi...

03/15/2018

Journal of Clinical Pathways

Research Reports

Effectiveness of Eribulin in Metastatic Breast Cancer Patients With Poor Prognostic Indicators in the United States

06/21/2021

Bruce A. Feinberg , DO;

Talia Miller , MSW, MPH;

Jingchuan Zhang , PhD;

Marjorie E. Zettler , PhD, MPH;

Sarah S. Mougalian , MD;

A retrospective real-world study demonstrates the clinical effectiveness of eribulin in subgroups of MBC patients with poor prognostic characteristics, when used in accordance with the approved US indication.

A retrospective real-world study...

06/21/2021

Journal of Clinical Pathways

Feature

Positioning CAR-T Therapy Into Clinical Pathways for Non-Hodgkin B-Cell Lymphoma and Beyond

03/23/2017

Sandeep Parsad , PharmD, BCOP;

Chadi Nabhan , MD, MBA, FACP;

Bruce A. Feinberg , DO;

Abstract: Enthusiasm for immunotherapy has spread throughout the oncology community in recent years, as therapies harnessing the body’s ability to fight cancers have offered the potential for remission and even cure...

...

03/23/2017

Journal of Clinical Pathways

From the Field

Mock Clinical Pathways: A Method for Exploring the Oncology Clinical Pathway Development Process

05/06/2016

Bing-E Xu , PhD;

Bruce A. Feinberg , DO;

Monica Lingam , MS;

Abstract: Clinical pathways are a critical structural element in the effort to reduce variation in health care as well as to make costs and outcomes more predictable, measurable, and accountable. A mock clinical...

...

05/06/2016

Journal of Clinical Pathways